Medicines Articles
Hailed as a major advancement in the fight against skin cancer, the U.S. Food and Drug Administration (FDA) has approved a new immune-based therapy for treating metastatic melanoma.
The U.S. Food and DrugAdministration (FDA) approved BioProducts Laboratory’s Gammaplex(immune globulin intravenous [human]5% liquid) for pediatric patients 2 years of age and older who have primary immunodeficiency disease (PI).
The U.S. Food and Drug Administration(FDA) has approved revised product labeling for Wilate (von Willebrand factor/coagulation factorVIII complex [human]) to include prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von Willebrand disease patients.
A new report shows that stem cell transplants might soon offer multiple sclerosis (MS) patients an effective way to stave off relapses and improve their overall neurologic condition.
Scientists at the University of South Australia and colleagues from Third Military Medical University in Chongqing, China, have found that the drug Edaravone alleviates Alzheimer’s disease pathologies at multiple levels and improves learning and memory functions in mice.
The Centers for Medicare and Medicaid Services (CMS) has expanded coverage to include in-home use of HYQVIA(immune globulin infusion 10 percent [human] with recombinant humanhyaluronidase) to treat primary immunodeficiency patients.
Pfizer (a licensee of Gliknik Inc.) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its recombinant intravenous immune globulin (IVIG)-mimetic drug
GL-2045 to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
CSL Behring’s Biologics License Application for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin, rIX-FP, has been accepted for review by the U.S.
Octapharma USA has launched the Octapharma Co-Pay Assistance Program available to von Willebrand’s disease patients who are currently receiving Wilate or have a prescription to begin therapy.
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded approximately $12 million to BioCryst Pharmaceuticals for the advanced development of a promising experimental drug for Ebola.
Novo Nordisk has launched Novoeight (antihemophilic factor [recombinant]) in the U.S. for people living with hemophilia A.
A new experimental drug could boost the immune system in older adults by as much as 20 percent, as well as help them to delay other aging effects.